Related references
Note: Only part of the references are listed.A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease
Brian Feagan et al.
GASTROENTEROLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
J. Verbeeck et al.
GUT (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
The genetics and immunopathogenesis of inflammatory bowel disease
Judy H. Cho
NATURE REVIEWS IMMUNOLOGY (2008)
Genetic factors associated with the development of inflammatory bowel disease
Jesus K. Yamamoto-Furusho
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Stephen B. Hanauer
GUT (2007)
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?
Joel R. Rosh et al.
INFLAMMATORY BOWEL DISEASES (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients:: A project of the European Collaborative Study Group on Inflammatory Bowel Disease
Shmuel Odes et al.
INFLAMMATORY BOWEL DISEASES (2007)
American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
M. Clark et al.
GASTROENTEROLOGY (2007)
Safety of biologic therapy
Wojciech Blonski et al.
INFLAMMATORY BOWEL DISEASES (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Enzymes in feces: Useful markers of chronic inflammatory bowel disease
Imerio Angriman et al.
CLINICA CHIMICA ACTA (2007)
Meta-analysis: mortality in Crohn's disease
C. Canavan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Review article: the burden of hepatic encephalopathy
F. F. Poordad
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Medical therapy for Crohn's disease: Top-down or step-up?
Filip Baert et al.
DIGESTIVE DISEASES (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
The natural history of corticosteroid therapy for ulcerative colitis in children
Jeffrey Hyams et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Corticosteroid therapy in the age of infliximab: Acute and 1-year outcomes in newly diagnosed children with Crohn's disease
James Markowitz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Long-term effectiveness of azathioprine in IBD beyond 4 years:: A European multicenter study in 1176 patients
Martin H. Holtmann et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Genetic variants and the risk of Crohn's disease:: what does it mean for future disease management?
Helga-Paula Toeroek et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease
Iris Dotan et al.
GASTROENTEROLOGY (2006)
The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort
G. -T. Ho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo-controlled trial
R Westhovens et al.
ARTHRITIS AND RHEUMATISM (2006)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
Risk factors for initial surgery in pediatric patients with Crohn's disease
N Gupta et al.
GASTROENTEROLOGY (2006)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
P Rutgeerts et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Predictors of Crohn's disease
L Beaugerie et al.
GASTROENTEROLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression
MC Dubinsky et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study
Frank L. Wolters et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
Anti-glycan antibodies as biomarkers for diagnosis and prognosis
N. Dotan et al.
LUPUS (2006)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2005)
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery
J Cosnes et al.
GUT (2005)
Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children
SK Gupta et al.
INFLAMMATORY BOWEL DISEASES (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease
WS Mow et al.
GASTROENTEROLOGY (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Isolation of peptides useful for differential diagnosis of Crohn's disease and ulcerative colitis
H Saito et al.
GUT (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review
EV Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
WA Faubion et al.
GASTROENTEROLOGY (2001)
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics
EA Vasiliauskas et al.
GUT (2000)
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease
J Markowitz et al.
GASTROENTEROLOGY (2000)
Share Paper
